Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.
ApexOnco Front Page
Recent articles
AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.
Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.
Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?
